Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2023 | Phase III trial update of P2B001 for Parkinson’s disease

Cheryl Fitzer-Attas, PhD, ClinMed LLC, describes the findings of a randomized Phase III trial investigating P2B001 for the treatment of Parkinson’s disease (PD). The trial had four arms –P2B001, pramipexole-extended-release-0.6mg, rasagiline-extended-release-0.75mg, or commercially available extended-release pramipexole. P2B001 had the highest efficacy and lowest levels of daytime sleepiness compared to commercially available pramipexole, as measured by the Epworth sleepiness scale. P2B001 also had lower adverse effects than marketed pramipexole (15% and 31%, respectively). This extended to hypertension (3% P2B001; 12% pramipexole) and dopaminergic adverse effects (45% P2B001; 66% pramipexole). This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Fitzer-Attas disclosures are that my company, ClinMed LLC, provides Clinical and Medical Affairs services to Pharma Two B.